Amrutanjan Health Care Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 22, 2025, 10:17 pm

Market Cap	1,976 Cr.
Current Price	684
High / Low	863/548
Stock P/E	40.0
Book Value	103
Dividend Yield	0.67 %
ROCE	21.3 %
ROE	15.5 %
Face Value	1.00
PEG Ratio	-9.98

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Amrutanjan Health Care Ltd

Competitors of Amrutanjan Health Care Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	161 Cr.	114	247/84.3	23.3	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	6.06 Cr.	3.17	4.33/2.75		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	46.0 Cr.	62.0	94.9/44.5	15.6	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	34.3 Cr.	23.4	29.0/13.1	35.0	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	17,741.31 Cr	1,130.31		44.29	182.59	0.34%	16.00%	16.30%	6.24

All Competitor Stocks of Amrutanjan Health Care Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	111	107	71	111	98	100	78	99	117	127	84	110	123
Expenses	85	90	68	95	85	87	71	92	95	111	80	96	99
Operating Profit	26	16	3	16	12	13	7	7	22	16	4	14	23
OPM %	23%	15%	5%	14%	12%	13%	9%	7%	18%	13%	4%	12%	19%
Other Income	3	5	3	3	4	5	4	4	4	5	4	4	4
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	2	1	1	1	2	2	2	2	2	2
Profit before tax	28	20	5	17	15	16	9	9	24	20	6	16	26
Tax %	26%	27%	30%	27%	26%	23%	26%	26%	26%	30%	27%	26%	26%
Net Profit	21	15	4	13	11	13	7	7	17	14	5	12	19
EPS in Rs	7.04	5.03	1.25	4.37	3.66	4.34	2.40	2.37	6.04	4.72	1.60	4.08	6.66

Last Updated: February 28, 2025, 8:37 pm

Below is a detailed analysis of the quarterly data for Amrutanjan Health Care Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 123.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Sep 2024) to 123.00 Cr., marking an increase of 13.00 Cr..
For Expenses, as of Dec 2024, the value is 99.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.00 Cr. (Sep 2024) to 99.00 Cr., marking an increase of 3.00 Cr..
For Operating Profit, as of Dec 2024, the value is 23.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Sep 2024) to 23.00 Cr., marking an increase of 9.00 Cr..
For OPM %, as of Dec 2024, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Sep 2024) to 19.00%, marking an increase of 7.00%.
For Other Income, as of Dec 2024, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 4.00 Cr..
For Interest, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Depreciation, as of Dec 2024, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 2.00 Cr..
For Profit before tax, as of Dec 2024, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Sep 2024) to 26.00 Cr., marking an increase of 10.00 Cr..
For Tax %, as of Dec 2024, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 26.00%.
For Net Profit, as of Dec 2024, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Sep 2024) to 19.00 Cr., marking an increase of 7.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 6.66. The value appears strong and on an upward trend. It has increased from 4.08 (Sep 2024) to 6.66, marking an increase of 2.58.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 9:18 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	128	131	154	174	207	220	253	261	333	406	380	421	443
Expenses	109	108	130	143	178	192	222	231	258	326	335	369	387
Operating Profit	19	23	25	32	29	28	31	31	75	80	45	52	57
OPM %	15%	18%	16%	18%	14%	13%	12%	12%	22%	20%	12%	12%	13%
Other Income	4	3	5	6	7	8	7	8	11	15	15	16	18
Interest	2	2	1	0	0	0	0	0	1	1	0	0	0
Depreciation	3	3	2	3	2	3	3	4	4	4	5	6	6
Profit before tax	18	21	26	35	34	33	35	34	82	91	54	62	68
Tax %	32%	32%	35%	35%	35%	39%	29%	27%	25%	26%	26%	27%
Net Profit	12	15	17	22	22	20	25	25	61	67	40	45	49
EPS in Rs	4.15	4.97	5.86	7.68	7.47	6.84	8.39	8.58	20.93	22.99	13.63	15.55	17.06
Dividend Payout %	36%	32%	30%	25%	26%	22%	26%	24%	20%	20%	34%	30%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	25.00%	13.33%	29.41%	0.00%	-9.09%	25.00%	0.00%	144.00%	9.84%	-40.30%	12.50%
Change in YoY Net Profit Growth (%)	0.00%	-11.67%	16.08%	-29.41%	-9.09%	34.09%	-25.00%	144.00%	-134.16%	-50.13%	52.80%

Amrutanjan Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	12%
5 Years:	11%
3 Years:	8%
TTM:	12%

Compounded Profit Growth
10 Years:	11%
5 Years:	13%
3 Years:	-10%
TTM:	12%

Stock Price CAGR
10 Years:	11%
5 Years:	12%
3 Years:	-9%
1 Year:	2%

Return on Equity
10 Years:	20%
5 Years:	21%
3 Years:	19%
Last Year:	15%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:43 am

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	3	3	3	3	3	3	3	3	3	3	3	3	3
Reserves	85	94	102	118	113	126	143	156	213	262	288	286	295
Borrowings	13	6	0	0	2	0	0	2	1	1	1	2	2
Other Liabilities	26	22	25	28	34	38	42	44	57	84	70	77	83
Total Liabilities	127	124	130	149	152	166	188	205	274	350	362	367	383
Fixed Assets	17	15	13	22	27	28	26	26	23	28	49	50	51
CWIP	1	1	4	1	1	0	0	0	2	17	1	2	1
Investments	30	14	14	10	10	8	18	18	18	13	5	0	0
Other Assets	79	95	100	116	115	131	144	161	232	291	307	315	331
Total Assets	127	124	130	149	152	166	188	205	274	350	362	367	383

Below is a detailed analysis of the balance sheet data for Amrutanjan Health Care Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
For Reserves, as of Sep 2024, the value is ₹295.00 Cr.. The value appears strong and on an upward trend. It has increased from 286.00 Cr. (Mar 2024) to ₹295.00 Cr., marking an increase of 9.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹83.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.00 Cr. (Mar 2024) to ₹83.00 Cr., marking an increase of 6.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹383.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 367.00 Cr. (Mar 2024) to ₹383.00 Cr., marking an increase of 16.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹51.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Mar 2024) to ₹51.00 Cr., marking an increase of 1.00 Cr..
For CWIP, as of Sep 2024, the value is ₹1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to ₹1.00 Cr., marking a decrease of 1.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹331.00 Cr.. The value appears strong and on an upward trend. It has increased from 315.00 Cr. (Mar 2024) to ₹331.00 Cr., marking an increase of 16.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹383.00 Cr.. The value appears strong and on an upward trend. It has increased from 367.00 Cr. (Mar 2024) to ₹383.00 Cr., marking an increase of 16.00 Cr..

Notably, the Reserves (295.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	8	18	19	21	8	19	21	18	91	52	20	28
Cash from Investing Activity +	16	16	-5	1	-0	-8	-11	-14	-88	-36	-2	19
Cash from Financing Activity +	-17	-14	-12	-11	-5	-9	-7	-12	-7	-17	-15	-48
Net Cash Flow	8	20	2	12	3	2	3	-7	-4	-1	3	-1

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	6.00	17.00	25.00	32.00	27.00	28.00	31.00	29.00	74.00	79.00	44.00	50.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	78	66	62	55	51	46	47	37	19	34	32	42
Inventory Days	44	45	44	44	44	40	45	74	45	53	58	50
Days Payable	55	44	46	51	110	102	92	98	106	122	95	96
Cash Conversion Cycle	67	67	61	48	-15	-16	0	13	-41	-35	-6	-5
Working Capital Days	57	54	42	45	80	26	30	71	29	92	117	173
ROCE %	20%	24%	26%	29%	28%	25%	25%	23%	44%	38%	19%	21%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	50.02%	50.02%	50.02%	50.02%	50.03%	50.03%	50.59%	50.59%	50.59%	50.58%	46.52%	46.52%
FIIs	1.43%	1.42%	0.87%	0.76%	0.68%	0.69%	0.75%	0.80%	1.38%	1.55%	2.34%	2.30%
DIIs	6.14%	6.16%	6.30%	6.39%	7.18%	7.22%	7.10%	7.24%	7.29%	7.32%	10.60%	11.13%
Public	42.23%	42.21%	42.62%	42.65%	41.93%	41.87%	41.39%	41.19%	40.66%	40.47%	40.50%	40.01%
Others	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.07%	0.07%	0.04%	0.04%
No. of Shareholders	67,323	66,173	71,064	72,104	69,947	71,428	72,002	68,404	62,664	57,169	54,536	53,856

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
DSP Small Cap Fund	1,466,269	0.69	110.79	1,466,269	2025-04-22 15:57:00	0%
Sundaram Small Cap Fund	484,538	1.07	36.61	484,538	2025-04-22 15:57:00	0%
ICICI Prudential FMCG Fund - Dividend	34,772	0.15	2.63	34,772	2025-04-22 15:57:00	0%
ICICI Prudential FMCG Fund - Growth	34,772	0.15	2.63	34,772	2025-04-22 15:57:00	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	14.47	14.08	10.31	8.51	6.92
Diluted EPS (Rs.)	14.47	14.08	10.31	8.51	6.92
Cash EPS (Rs.)	16.43	16.37	12.51	10.98	9.47
Book Value[Excl.RevalReserv]/Share (Rs.)	86.22	74.40	64.97	61.06	56.29
Book Value[Incl.RevalReserv]/Share (Rs.)	86.22	74.40	64.97	61.06	56.29
Revenue From Operations / Share (Rs.)	153.25	127.77	113.97	96.97	94.18
PBDIT / Share (Rs.)	23.16	24.95	19.32	16.93	14.83
PBIT / Share (Rs.)	21.20	22.66	17.13	14.47	12.28
PBT / Share (Rs.)	22.75	22.36	16.64	13.26	10.59
Net Profit / Share (Rs.)	14.47	14.08	10.31	8.51	6.92
NP After MI And SOA / Share (Rs.)	14.47	14.08	10.31	8.51	6.92
PBDIT Margin (%)	15.11	19.52	16.95	17.46	15.75
PBIT Margin (%)	13.83	17.73	15.02	14.92	13.04
PBT Margin (%)	14.84	17.50	14.60	13.67	11.24
Net Profit Margin (%)	9.43	11.01	9.04	8.78	7.34
NP After MI And SOA Margin (%)	9.43	11.01	9.04	8.78	7.34
Return on Networth / Equity (%)	16.77	18.92	15.87	13.94	12.29
Return on Capital Employeed (%)	23.87	29.45	25.52	22.73	20.83
Return On Assets (%)	13.07	14.65	12.16	10.34	8.14
Total Debt / Equity (X)	0.01	0.02	0.02	0.08	0.18
Asset Turnover Ratio (%)	1.48	1.35	1.30	1.12	1.00
Current Ratio (X)	3.46	3.59	3.20	2.87	1.67
Quick Ratio (X)	3.15	3.27	2.87	2.55	1.40
Inventory Turnover Ratio (X)	7.67	7.09	6.93	6.06	5.44
Dividend Payout Ratio (NP) (%)	0.00	27.34	33.93	37.58	43.33
Dividend Payout Ratio (CP) (%)	0.00	23.52	27.97	29.14	31.67
Earning Retention Ratio (%)	0.00	72.66	66.07	62.42	56.67
Cash Earning Retention Ratio (%)	0.00	76.48	72.03	70.86	68.33
Interest Coverage Ratio (X)	78.72	83.47	39.72	14.01	8.75
Interest Coverage Ratio (Post Tax) (X)	43.91	48.10	22.20	8.05	5.08
Enterprise Value (Cr.)	817.64	564.15	663.81	156.21	169.76
EV / Net Operating Revenue (X)	3.65	3.02	3.99	1.10	1.23
EV / EBITDA (X)	24.16	15.47	23.51	6.31	7.83
MarketCap / Net Operating Revenue (X)	3.85	3.27	4.20	1.29	1.23
Retention Ratios (%)	0.00	72.65	66.06	62.41	56.66
Price / BV (X)	6.85	5.61	7.36	2.06	2.06
Price / Net Operating Revenue (X)	3.85	3.27	4.20	1.29	1.23
EarningsYield	0.02	0.03	0.02	0.06	0.05

After reviewing the key financial ratios for Amrutanjan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 17, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
For Diluted EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
For Cash EPS (Rs.), as of Mar 17, the value is 16.43. This value is within the healthy range. It has increased from 16.37 (Mar 16) to 16.43, marking an increase of 0.06.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 153.25. It has increased from 127.77 (Mar 16) to 153.25, marking an increase of 25.48.
For PBDIT / Share (Rs.), as of Mar 17, the value is 23.16. This value is within the healthy range. It has decreased from 24.95 (Mar 16) to 23.16, marking a decrease of 1.79.
For PBIT / Share (Rs.), as of Mar 17, the value is 21.20. This value is within the healthy range. It has decreased from 22.66 (Mar 16) to 21.20, marking a decrease of 1.46.
For PBT / Share (Rs.), as of Mar 17, the value is 22.75. This value is within the healthy range. It has increased from 22.36 (Mar 16) to 22.75, marking an increase of 0.39.
For Net Profit / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
For PBDIT Margin (%), as of Mar 17, the value is 15.11. This value is within the healthy range. It has decreased from 19.52 (Mar 16) to 15.11, marking a decrease of 4.41.
For PBIT Margin (%), as of Mar 17, the value is 13.83. This value is within the healthy range. It has decreased from 17.73 (Mar 16) to 13.83, marking a decrease of 3.90.
For PBT Margin (%), as of Mar 17, the value is 14.84. This value is within the healthy range. It has decreased from 17.50 (Mar 16) to 14.84, marking a decrease of 2.66.
For Net Profit Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
For NP After MI And SOA Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
For Return on Networth / Equity (%), as of Mar 17, the value is 16.77. This value is within the healthy range. It has decreased from 18.92 (Mar 16) to 16.77, marking a decrease of 2.15.
For Return on Capital Employeed (%), as of Mar 17, the value is 23.87. This value is within the healthy range. It has decreased from 29.45 (Mar 16) to 23.87, marking a decrease of 5.58.
For Return On Assets (%), as of Mar 17, the value is 13.07. This value is within the healthy range. It has decreased from 14.65 (Mar 16) to 13.07, marking a decrease of 1.58.
For Total Debt / Equity (X), as of Mar 17, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 16) to 0.01, marking a decrease of 0.01.
For Asset Turnover Ratio (%), as of Mar 17, the value is 1.48. It has increased from 1.35 (Mar 16) to 1.48, marking an increase of 0.13.
For Current Ratio (X), as of Mar 17, the value is 3.46. This value exceeds the healthy maximum of 3. It has decreased from 3.59 (Mar 16) to 3.46, marking a decrease of 0.13.
For Quick Ratio (X), as of Mar 17, the value is 3.15. This value exceeds the healthy maximum of 2. It has decreased from 3.27 (Mar 16) to 3.15, marking a decrease of 0.12.
For Inventory Turnover Ratio (X), as of Mar 17, the value is 7.67. This value is within the healthy range. It has increased from 7.09 (Mar 16) to 7.67, marking an increase of 0.58.
For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 27.34 (Mar 16) to 0.00, marking a decrease of 27.34.
For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.52 (Mar 16) to 0.00, marking a decrease of 23.52.
For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 72.66 (Mar 16) to 0.00, marking a decrease of 72.66.
For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.48 (Mar 16) to 0.00, marking a decrease of 76.48.
For Interest Coverage Ratio (X), as of Mar 17, the value is 78.72. This value is within the healthy range. It has decreased from 83.47 (Mar 16) to 78.72, marking a decrease of 4.75.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 43.91. This value is within the healthy range. It has decreased from 48.10 (Mar 16) to 43.91, marking a decrease of 4.19.
For Enterprise Value (Cr.), as of Mar 17, the value is 817.64. It has increased from 564.15 (Mar 16) to 817.64, marking an increase of 253.49.
For EV / Net Operating Revenue (X), as of Mar 17, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 3.02 (Mar 16) to 3.65, marking an increase of 0.63.
For EV / EBITDA (X), as of Mar 17, the value is 24.16. This value exceeds the healthy maximum of 15. It has increased from 15.47 (Mar 16) to 24.16, marking an increase of 8.69.
For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 72.65 (Mar 16) to 0.00, marking a decrease of 72.65.
For Price / BV (X), as of Mar 17, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 5.61 (Mar 16) to 6.85, marking an increase of 1.24.
For Price / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
For EarningsYield, as of Mar 17, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 16) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Amrutanjan Health Care Ltd as of April 23, 2025 is: 514.30

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 23, 2025, Amrutanjan Health Care Ltd is Overvalued by 24.81% compared to the current share price 684.00

Intrinsic Value of Amrutanjan Health Care Ltd as of April 23, 2025 is: 493.69

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 23, 2025, Amrutanjan Health Care Ltd is Overvalued by 27.82% compared to the current share price 684.00

Last 5 Year EPS CAGR: -4.01%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 26.83%, which is a positive sign. The company has higher reserves (175.46 cr) compared to borrowings (2.31 cr), indicating strong financial stability. The company has shown consistent growth in sales (270.08 cr) and profit (45.62 cr) over the years.	The stock has a high average Working Capital Days of 68.00, which may not be favorable. The stock has a high average Cash Conversion Cycle of 11.50, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amrutanjan Health Care Ltd:
1. Net Profit Margin: 9.43%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.87% (Industry Average ROCE: 15.87%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 16.77% (Industry Average ROE: 15.77%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 43.91
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 3.15
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 40 (Industry average Stock P/E: 35.57)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Amrutanjan Health Care Ltd. is a Public Limited Listed company incorporated on 09/09/1936 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24231TN1936PLC000017 and registration number is 000017. Currently Company is involved in the business activities of Manufacture of `ayurvedic' or `unani' pharmaceutical preparation. Company's Total Operating Revenue is Rs. 421.23 Cr. and Equity Capital is Rs. 2.89 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	No.103 (Old No.42-45), Chennai (Madras) Tamil Nadu 600004	shares@amrutanjan.com http://www.amrutanjan.com

Management
Name	Position Held
Mr. S Sambhu Prasad	Chairman & Managing Director
Mr. G Raghavan	Non Executive Director
Ms. Ramaa Prabhakar Arikirevula	Non Executive Director
Ms. Meenalochani Raghunathan	Ind. Non-Executive Director
Mr. Raja Venkataraman	Ind. Non-Executive Director
Mr. S Muralidharan	Ind. Non-Executive Director

FAQ

What is the intrinsic value of Amrutanjan Health Care Ltd?

Amrutanjan Health Care Ltd's intrinsic value (as of 23 April 2025) is ₹514.30 — 24.81% lower the current market price of 684.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,976 Cr. market cap, FY2025-2026 high/low of ₹863/548, reserves of 295 Cr, and liabilities of 383 Cr.

What is the Market Cap of Amrutanjan Health Care Ltd?

The Market Cap of Amrutanjan Health Care Ltd is 1,976 Cr..

What is the current Stock Price of Amrutanjan Health Care Ltd as on 23 April 2025?

The current stock price of Amrutanjan Health Care Ltd as on 23 April 2025 is 684.

What is the High / Low of Amrutanjan Health Care Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Amrutanjan Health Care Ltd stocks is ₹863/548.

What is the Stock P/E of Amrutanjan Health Care Ltd?

The Stock P/E of Amrutanjan Health Care Ltd is 40.0.

What is the Book Value of Amrutanjan Health Care Ltd?

The Book Value of Amrutanjan Health Care Ltd is 103.

What is the Dividend Yield of Amrutanjan Health Care Ltd?

The Dividend Yield of Amrutanjan Health Care Ltd is 0.67 %.

What is the ROCE of Amrutanjan Health Care Ltd?

The ROCE of Amrutanjan Health Care Ltd is 21.3 %.

What is the ROE of Amrutanjan Health Care Ltd?

The ROE of Amrutanjan Health Care Ltd is 15.5 %.

What is the Face Value of Amrutanjan Health Care Ltd?

The Face Value of Amrutanjan Health Care Ltd is 1.00.